Printer Friendly

Amneal Expands Generic Portfolio with Launch of Alprazolam ER and Benazepril HCI Tablets.

HAUPPAUGE, N.Y. -- Amneal Pharmaceuticals is pleased to announce the availability of its Alprazolam Extended Release Tablets in strengths of 0.5 mg, 1 mg, 2 mg and 3 mg. The company also announces the availability of its Benazepril HCI Tablets in strengths of 5 mg, 10 mg, 20 mg and 40 mg.

Alprazolam ER is an anti-anxiety Schedule-IV controlled substance indicated for the treatment of panic disorder with or without agoraphobia. It is an AB-rated, therapeutically equivalent alternative to the brand, Xanax[R] XR (a trademark of The Upjohn Company). Amneal received U.S. FDA approval to manufacture Alprazolam ER as a result of acquiring Interpharm's strong product line last year. The Amneal generic is available in a 60-count size for all strengths, which will begin shipping on June 15, 2009.

Amneal has also been granted FDA approval to manufacture Benazepril HCI. Benazepril HCI is an AB-rated, bioequivalent alternative to the brand, Lotensin[R] (a trademark of Ciba-Geigy), and is indicated for the treatment of hypertension. All four strengths of the generic are available in 100- and 500-count sizes, which began shipping on June 1, 2009.

"The introduction of Alprazolam ER and Benazepril HCI supports Amneal's growth strategy of adding diverse, more sophisticated lines such as modified release medications, controlled substances and hormonal products," said Jim Luce, Amneal Executive Vice President, Sales & Marketing. He continued, "Amneal's rapidly expanding portfolio of high quality products and dedication to customer service are enabling us to develop a significant presence in the generic prescription marketplace."

Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as "Generic's New Generation", the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline. Rapid ANDA approvals and diverse product acquisitions are key to Amneal's aggressive growth strategy, as is the company's strong commitment to deep customer relationships and maximum value creation. Amneal delivers high quality products, superior service levels and dynamic value throughout the pharmaceutical industry. For more information, visit
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 15, 2009
Previous Article:A.M. Best Affirms Ratings of TT Club.
Next Article:OASIS Introduces Non-Assertion Mode to Its Intellectual Property Rights Policy for Standards Development.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters